Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial - Summary - MDSpire

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial

  • By

  • Filip Ventorp

  • Marie Asp

  • Sofia Olsson

  • Jesper Lindahl

  • Stefan Möller

  • Martina Svensson

  • Filip Ängeby

  • Armida Pravdinske

  • Johanna Tjernberg

  • Susann Schrey

  • Darya Ståhl

  • Viktor Magnusson

  • Emilia Eliasson

  • Anna Agelii-Weber

  • Erika Stålhammar

  • Danielle van Westen

  • Tomas Deierborg

  • Kristoffer N. T. Månsson

  • Diego A. Pizzagalli

  • Åsa Hammar

  • Åsa B. Tornberg

  • Johannes Björkstrand

  • Daniel Lindqvist

  • June 12, 2026

  • 0 min

Share

Objective:

To investigate the efficacy of high-dose pramipexole on anhedonia and related symptoms in mood disorders.

Approach:
    Key Findings:
    • 284 patients screened; 85 randomized to pramipexole (n=43) or placebo (n=42).
    • Participants had significant anhedonia defined by SHAPS scores.
    • Demographic data indicated a mean age of 47.22 years, with 45.12% female participants.
    Interpretation:

    Remove speculative language and unsupported conclusions.

    Limitations:
    • Study sample size may limit generalizability.
    • Short duration of the RCT may not capture long-term effects.
    Conclusion:

    Revise to summarize findings without editorial interpretation.

Original Source(s)

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial

  • by Filip Ventorp, Marie Asp, Sofia Olsson, Jesper Lindahl, Stefan Möller, Martina Svensson, Filip Ängeby, Armida Pravdinske, Johanna Tjernberg, Susann Schrey, Darya Ståhl, Viktor Magnusson, Emilia Eliasson, Anna Agelii-Weber, Erika Stålhammar, Danielle van Westen, Tomas Deierborg, Kristoffer N. T. Månsson, Diego A. Pizzagalli, Åsa Hammar, Åsa B. Tornberg, Johannes Björkstrand, Daniel Lindqvist

  • June 12, 2026

Related Content

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Efficacy and safety of sini powder combined with Xiaoxianxiong decoction for adolescent depression with liver qi stagnation and phlegm-heat obstruction syndrome: a randomized controlled trial